Business
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announces that it will present multiple research results at the 34th European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France from September 17-20. Specifically, post hoc analysis of Phase 2
About this update from Innovent Biologics, Inc.
[{"type":"text","content":"SAN FRANCISCO and SUZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announces that it will present multiple research results at the 34th European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, France from September 17-20. Specifically, post hoc analysis of Phase 2 and Phase 3 clinical studies of IBI112 (IL-23p19 monoclonal antibody, picankibart), as well as preclinical study results of IBI3013 (IL-15 monoclonal antibody) and IAR129 (IL-4R/OX40L bispecific antibody) will be showcased via ePoster. Details are listed below:","length":846,"tagName":"p"},{"type":"text","content":"Title: Development and Characterization of IBI3013, a Novel Half-life Extended Monoclonal Antibody Targeting Interleukin-15 (IL-15) Abstract #: 1882Presentation Form: ePosterTime: 2025 September 17, 07:00 AM (CEST)","length":218,"tagName":"p"},{"type":"text","content":"Title: Development and characterization of IAR129, a novel bispecific antibody co-blocking IL-4Ra and OX40L for atopic dermatitis Abstract #: 2648Presentation Form: ePosterTime: 2025 September 17, 07:00 AM (CEST)","length":216,"tagName":"p"},{"type":"text","content":"Title: Efficacy and safety of picankibart in patients with psoriasis who had been treated with biologics: a multicenter, open-label Phase 2 trial Abstract #: 1706 Presentation Form: ePosterTime: 2025 September 17, 07:00 AM (CEST)","length":239,"tagName":"p"},{"type":"text","content":"Title: Efficacy of picankibart in moderate-to-severe plaque psoriasis patients with scalp psoriasis: a post-hoc analysis of a Phase 3, randomized, double-blind trial Abstract #: 4799Presentation Form: ePosterTime: 2025 September 17, 07:00 AM (CEST)","length":251,"tagName":"p"},{"type":"text","content":"Title: Efficacy of picankibart in genital psoriasis: results from the Phase 3 randomized, double-blind CLEAR-1 study Abstract #: 6421Presentation Form: ePosterTime: 2025 September 17, 07:00 AM (CEST)","length":208,"tagName":"p"},{"type":"text","content":"Title: Efficacy of a new IL-23p19 inhibitor picankibart in the treatment o...